benserazide has been researched along with Hypertension in 9 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
Excerpt | Relevance | Reference |
---|---|---|
"We examined the time course and extent to which central and peripheral mechanisms contribute to the short-term effects of a 500-mg oral dose of alpha-methyldopa on supine mean arterial pressure, cardiac output, and total peripheral resistance, as well as its effects on total urinary excretion of norepinephrine and its metabolites, in five subjects with essential hypertension." | 5.06 | Evidence for a predominantly central hypotensive effect of alpha-methyldopa in humans. ( Bobik, A; Jackman, G; Jennings, G; Korner, P; Oddie, C, 1986) |
"The peripheral decarboxylase inhibitor carbidopa, given (100 mg/day) for 6 wk in a double-blind trial, lowered supine diastolic pressure of 10 patients with essential hypertension treated with alpha methyldopa by a small (6 mm Hg) but significant (p less than 0." | 5.04 | Clinical and cardiovascular effects of alpha methyldopa in combination with decarboxylase inhibitors. ( Dollery, CT; Kersting, F; Reid, JL, 1977) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (77.78) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Tischendorf, JJ | 1 |
Karges, W | 1 |
Schöfl, C | 1 |
Kersting, F | 1 |
Reid, JL | 1 |
Dollery, CT | 1 |
Planz, G | 1 |
Gierlichs, HW | 1 |
Hawlina, A | 1 |
Planz, R | 1 |
Stephany, W | 1 |
Rahn, KH | 1 |
Hansell, P | 1 |
Sjöquist, M | 1 |
Bobik, A | 1 |
Jennings, G | 1 |
Jackman, G | 1 |
Oddie, C | 1 |
Korner, P | 1 |
Day, MD | 1 |
Roach, AG | 1 |
Whiting, RL | 1 |
Boudin, G | 1 |
Pépin, B | 1 |
Guillard, A | 1 |
Fabiani, JM | 1 |
Haguenau, M | 1 |
Nakamura, K | 2 |
Cohen, Y | 1 |
Wepierre, J | 1 |
Jacquot, C | 1 |
Rapin, J | 1 |
3 trials available for benserazide and Hypertension
Article | Year |
---|---|
Clinical and cardiovascular effects of alpha methyldopa in combination with decarboxylase inhibitors.
Topics: Adult; Benserazide; Blood Pressure; Carbidopa; Carboxy-Lyases; Clinical Trials as Topic; Cold Temper | 1977 |
Influence of the decarboxylase inhibitor benserazide on the antihypertensive effect and metabolism of alpha-methyldopa in patients with essential hypertension.
Topics: Adult; Benserazide; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Interactions | 1977 |
Evidence for a predominantly central hypotensive effect of alpha-methyldopa in humans.
Topics: Adult; Benserazide; Biological Availability; Blood Pressure; Blood-Brain Barrier; Female; Half-Life; | 1986 |
6 other studies available for benserazide and Hypertension
Article | Year |
---|---|
Catecholamine excess in a patient with restless legs syndrome treated with levodopa and benserazide.
Topics: Adult; Antiparkinson Agents; Benserazide; Catecholamines; Diagnosis, Differential; Drug Combinations | 2009 |
Dopamine receptor blockade and synthesis inhibition during exaggerated natriuresis in spontaneously hypertensive rats.
Topics: Animals; Benserazide; Dopamine Antagonists; Haloperidol; Hypertension; Isotonic Solutions; Male; Nat | 1992 |
The mechanism of the antihypertensive action of -methyldopa in hypertensive rats.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Desoxycorticoste | 1973 |
[Indications and results of monoamine treatment in parkinsonian syndromes].
Topics: Aged; Arrhythmias, Cardiac; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Combinations; | 1972 |
Proceedings: Further studies on the mechanisms of blood pressure lowering effect of L-DOPA and a peripheral decarboxylase inhibitor in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benserazide; Blood Pressure; Brain Chemistry; Carboxy-Lyases; Deso | 1974 |
[Relationship between the antihypertensive activity of methyldopa and the appearance of its metabolites in the heart and brain of the hypertensive rat].
Topics: Animals; Antihypertensive Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biotran | 1974 |